- Home
- XENE vs SUPN Comparison
XENE vs SUPN Comparison
Compare XENE & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XENE
- SUPN
- Stock Information
- Founded
- XENE 1996
- SUPN 2005
- Country
- XENE Canada
- SUPN United States
- Employees
- XENE N/A
- SUPN N/A
- Industry
- XENE Biotechnology: Pharmaceutical Preparations
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- XENE Health Care
- SUPN Health Care
- Exchange
- XENE Nasdaq
- SUPN Nasdaq
- Market Cap
- XENE 2.9B
- SUPN 2.6B
- IPO Year
- XENE 2014
- SUPN 2012
- Fundamental
- Price
- XENE $36.70
- SUPN $44.80
- Analyst Decision
- XENE Strong Buy
- SUPN Buy
- Analyst Count
- XENE 11
- SUPN 2
- Target Price
- XENE $52.73
- SUPN $43.00
- AVG Volume (30 Days)
- XENE 636.6K
- SUPN 654.2K
- Earning Date
- XENE 11-11-2025
- SUPN 11-03-2025
- Dividend Yield
- XENE N/A
- SUPN N/A
- EPS Growth
- XENE N/A
- SUPN 1411.53
- EPS
- XENE N/A
- SUPN 1.14
- Revenue
- XENE $7,500,000.00
- SUPN $665,125,000.00
- Revenue This Year
- XENE N/A
- SUPN $4.84
- Revenue Next Year
- XENE $207.88
- SUPN $17.69
- P/E Ratio
- XENE N/A
- SUPN $38.93
- Revenue Growth
- XENE N/A
- SUPN 5.55
- 52 Week Low
- XENE $26.74
- SUPN $29.16
- 52 Week High
- XENE $46.00
- SUPN $46.79
- Technical
- Relative Strength Index (RSI)
- XENE 49.37
- SUPN 58.16
- Support Level
- XENE $35.60
- SUPN $43.44
- Resistance Level
- XENE $39.55
- SUPN $46.72
- Average True Range (ATR)
- XENE 1.04
- SUPN 1.08
- MACD
- XENE -0.49
- SUPN -0.48
- Stochastic Oscillator
- XENE 25.94
- SUPN 40.60
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.